GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Synaptogenix Inc.
Synaptogenix is a biotech company developing drugs to treat Alzheimer's disease. Its stock price reflects the enormous potential of this market, but also the extremely high risks and long history of failure in this highly complex field of medicine.
Share prices of companies in the market segment - Neuro
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's disease. We've categorized it under "Neurology," and the chart below shows how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Synaptogenix is a biopharmaceutical company developing treatments for neurodegenerative diseases, particularly Alzheimer's disease. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Synaptogenix shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SNPX - Daily change in the company's share price Synaptogenix Inc.
Synaptogenix, Inc.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures its sensitivity to news about clinical trials of its Alzheimer's drugs.
Daily change in the price of a set of shares in a market segment - Neuro
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in biotech. The chart below illustrates the high volatility typical of this sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Synaptogenix is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Synaptogenix Inc.
Synaptogenix, Inc.'s year-to-date performance is a story of its struggle to develop a drug to treat Alzheimer's disease. Its 12-month market cap is entirely dependent on clinical trial data. The failure of a key study dealt a serious blow, and its valuation now reflects its belief that the company can find a new path.
Annual dynamics of market capitalization of the market segment - Neuro
As an early-stage biotech, Synaptogenix is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its Alzheimer's drugs. Its stock price will reflect investors' speculative beliefs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Synaptogenix, a biotech company plagued by research setbacks, tells the story of its struggle for survival through its performance. Its performance, compared to the market, reflects investors' confidence in the remaining drugs in its portfolio. It's a risky bet on the company's ability to recover.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Synaptogenix Inc.
Synaptogenix is a biotech company targeting Alzheimer's disease. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its lead drug are binary events, causing wild price fluctuations, typical in this risky field.
Monthly dynamics of market capitalization of the market segment - Neuro
Synaptogenix is a clinical-stage biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer's. The chart below illustrates the overall dynamics of the biotech sector, where developing drugs for the central nervous system is the riskiest, but also the most desirable, goal.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Synaptogenix is a biotech company developing a treatment for Alzheimer's disease. Its shares are extremely volatile and driven solely by news of clinical trials. Their performance is completely disconnected from the broader market, betting on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Synaptogenix Inc.
The weekly performance of Synaptogenix, a biotech company targeting Alzheimer's disease, reflects the complex path this field has taken. Share prices react to any news about the progress of clinical trials, where disappointments are far more common than breakthroughs.
Weekly dynamics of market capitalization of the market segment - Neuro
Synaptogenix develops drugs to treat neurodegenerative diseases such as Alzheimer's. The chart helps separate its own news-driven dynamics from the overall fluctuations in the neuroscience sector, revealing its place in this high-risk race.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Synaptogenix is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Synaptogenix is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
SNPX - Market capitalization of the company Synaptogenix Inc.
Synaptogenix's market capitalization tells the story of a biotech company focused on treating Alzheimer's disease. Its decline reflects the failure of its lead drug in clinical trials, an unfortunately common occurrence in this complex field of medicine.
SNPX - Share of the company's market capitalization Synaptogenix Inc. within the market segment - Neuro
Synaptogenix is a biotech company focused on treating Alzheimer's disease. Its share of the sector's market capitalization reflects both the high risks and the enormous potential for success. The chart below is a barometer of investor hopes for a breakthrough in one of the most complex areas of medicine.
Market capitalization of the market segment - Neuro
Synaptogenix is a clinical-stage biotech company developing drugs to treat Alzheimer's disease. The chart below shows the market capitalization of the neuroscience sector. Its dynamics reflect the enormous need for a treatment for this disease and the extremely high risks associated with its research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Synaptogenix is a biotech company developing therapies for Alzheimer's disease. Its market cap reflects the hope of a breakthrough in treating one of the most terrifying diseases of our time. Its volatility on the overall chart reflects the enormous challenges and potentially enormous rewards in this field.
Book value capitalization of the company, segment and market as a whole
SNPX - Book value capitalization of the company Synaptogenix Inc.
Synaptogenix's foundation is its capital invested in clinical trials of a drug for the treatment of Alzheimer's disease. Its book value reflects the financial basis for risky but potentially breakthrough developments in neuroscience. How has this biotech asset changed? The chart below shows its volatile history.
SNPX - Share of the company's book capitalization Synaptogenix Inc. within the market segment - Neuro
Synaptogenix develops drugs to treat Alzheimer's disease, which requires R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its work on one of medicine's most complex problems.
Market segment balance sheet capitalization - Neuro
Synaptogenix, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Synaptogenix's book value is its intellectual property for its Alzheimer's drug. The company's assets are the capitalized results of years of research. The chart shows how this biotech company, operating in one of the most complex areas of medicine, compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Synaptogenix Inc.
Synaptogenix is a biotech company working on a treatment for Alzheimer's disease. Its balance sheet is a cumulative research budget. Its market capitalization represents a pure, albeit extremely risky, hope for a breakthrough in one of the most complex areas of medicine. The MvsBCap_Co chart reflects both its enormous potential and its equally enormous risks.
Market to book capitalization ratio in a market segment - Neuro
Synaptogenix is a biotech company developing therapies for Alzheimer's disease. Its valuation on the chart is highly speculative and reflects both the enormous potential market and the extremely high risk of failure in this complex area of medicine.
Market to book capitalization ratio for the market as a whole
Synaptogenix, Inc. is a biotech company working on a treatment for Alzheimer's disease. Its market valuation is almost entirely based on the success of a single, potentially gigantic product. The chart shows an extreme risk-hope premium in biotech compared to the rest of the market.
Debts of the company, segment and market as a whole
SNPX - Company debts Synaptogenix Inc.
Synaptogenix, a biotech focused on treating Alzheimer's disease, uses capital to fund its high-risk clinical trials. This chart shows how the company raises funds to pursue one of the most complex and capital-intensive areas of pharmaceuticals, where the risk of failure is extremely high.
Market segment debts - Neuro
Synaptogenix is a clinical-stage biotech focused on Alzheimer's disease. Drug development in this area is extremely risky and expensive. This chart demonstrates that the company, like everyone else in this field, is financed exclusively through equity, as debt is unaffordable for such projects.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Synaptogenix Inc.
Synaptogenix is a biotech company developing drugs to treat Alzheimer's disease. This is one of the most complex and risky areas in pharmaceuticals. This chart shows how dependent the company is on external funding to conduct its expensive and lengthy clinical trials. It reflects the extremely high risk.
Market segment debt to market segment book capitalization - Neuro
Synaptogenix develops drugs to treat neurodegenerative diseases such as Alzheimer's, one of the most complex and risky areas in medicine. The chart shows how aggressively the sector uses debt to fund R&D, providing context for assessing Synaptogenix's financial strategy.
Debt to book value of all companies in the market
Synaptogenix, Inc., a clinical-stage biopharmaceutical company focused on Alzheimer's disease, operates in one of the riskiest areas of medicine. This chart, which reflects the overall debt load in the market, helps assess its financial risk. It shows how the company raises capital to fund its extremely expensive and time-consuming research.
P/E of the company, segment and market as a whole
P/E - Synaptogenix Inc.
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart shows how investors value its scientific developments. The valuation depends entirely on the results of clinical trials in this highly complex and risky field.
P/E of the market segment - Neuro
Synaptogenix's Alzheimer's disease treatment is a high-risk area. This chart shows the average valuation for biopharmaceutical companies. It makes clear that Synaptogenix's valuation is entirely dependent on investor faith in its scientific approach and clinical trial data, making it highly volatile.
P/E of the market as a whole
Synaptogenix is a biopharmaceutical company developing drugs to treat Alzheimer's disease. Its valuation is a bet on a breakthrough in one of the most complex areas of medicine. It is unrelated to the general economic trends shown in this chart and depends solely on clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Synaptogenix Inc.
The chart for Synaptogenix, Inc., a biopharmaceutical company developing drugs to treat Alzheimer's disease, illustrates market expectations for its clinical trials. It reflects the high risk and potential reward associated with finding a cure for this complex disease.
%20P%2FE%20Synaptogenix%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Synaptogenix-Inc.&v=1772513695868 "Chart of the company's future (projected) P/E Synaptogenix Inc.")
Future (projected) P/E of the market segment - Neuro
Synaptogenix is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's disease. This chart shows industry forecasts, helping to assess how the market views Synaptogenix's high-risk but potentially breakthrough approach in one of the most complex areas of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513695899 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Synaptogenix, Inc. is a biopharmaceutical company developing a treatment for Alzheimer's disease. It's the "holy grail" of the pharmaceutical industry, but also the biggest "graveyard" for clinical trials. The company's valuation is pure hope. This chart shows how prepared the market is for the riskiest bets in biotech.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513695900 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Synaptogenix Inc.
Synaptogenix, Inc. is a biopharmaceutical company developing therapies for neurodegenerative diseases such as Alzheimer's. While in the clinical stage, it is losing money. This chart illustrates the financial risks and enormous costs associated with solving one of the most complex problems in medicine.
Profit of companies in the market segment - Neuro
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's. This graph, which shows the sector's profitability, illustrates the complexity and risk involved in finding a cure for this disease. The company's success depends entirely on the clinical trial results of its lead candidate.
Overall market profit
Synaptogenix, Inc. is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's disease. This is one of the most complex and risky areas in medicine. This total return chart reflects the investment climate, which determines whether investors are willing to fund such long-term, high-risk projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Synaptogenix Inc.
Synaptogenix is a biopharmaceutical company developing therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its future depends entirely on the results of clinical trials. This chart reflects analysts' highly speculative expectations regarding the chances of success in this highly complex area of medicine.
%20profit%20of%20the%20company%20Synaptogenix%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Synaptogenix-Inc.&v=1772513695936 "Graph of future (projected) profit of the company Synaptogenix Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Synaptogenix is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's disease. Its future depends entirely on the results of clinical trials. This biotech chart reflects the overall investor interest in finding a cure for this complex disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513695944 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Synaptogenix is a biopharmaceutical company developing a treatment for Alzheimer's disease. Its future depends entirely on the results of clinical trials. The overall economic outlook, reflected in this chart, impacts the investment climate and the ability to attract the enormous capital required for such research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513695965 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Synaptogenix Inc.
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. For a clinical-stage company, this chart is key. It shows how investors view its scientific developments and future sales potential if successful.
P/S market segment - Neuro
Synaptogenix, Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's disease. The company's valuation is based on the future potential of its clinical developments. This chart, which displays the average valuation in the biotech industry, helps understand how investors' expectations for Synaptogenix's science compare to overall trends.
P/S of the market as a whole
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's disease. This chart, which reflects revenue estimates for real businesses, highlights that Synaptogenix's valuation represents a bet on a potential breakthrough in one of the most complex and in-demand areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Synaptogenix Inc.
Synaptogenix is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases such as Alzheimer's. This is a highly risky field. This chart reflects investor hopes for a scientific breakthrough that could lead to the first effective treatment for this disease.
%20P%2FS%20Synaptogenix%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Synaptogenix-Inc.&v=1772513696046 "The graph of the company's future (projected) P/S Synaptogenix Inc.")
Future (projected) P/S of the market segment - Neuro
Synaptogenix, Inc. is a late-stage clinical development biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease. This chart reflects average revenue expectations in the biotech sector and provides an insight into the market's perception of Synaptogenix's potential.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513696067 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Synaptogenix, Inc. is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This indicator reflects the market's collective expectations. Despite the high risks, a potential breakthrough in this field could bring enormous benefits to society and investors, fueling interest in the company.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513696073 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Synaptogenix Inc.
This chart shows the revenue of Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing a treatment for Alzheimer's disease. At this stage, its revenue, if any, comes not from sales but from grants and partnerships, reflecting progress in solving one of the most challenging medical problems.
Sales of companies in the market segment - Neuro
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's disease. This chart shows the potential market for CNS therapeutics. Although the company is in the clinical stage, its research is aimed at creating a breakthrough treatment for one of the most complex and widespread diseases of our time.
Overall market sales
Synaptogenix is a biopharmaceutical company developing drugs to treat Alzheimer's disease. Its market capitalization depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to fund high-risk projects in the field of neurodegenerative diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Synaptogenix Inc.
Synaptogenix is a clinical-stage biotech company developing a treatment for Alzheimer's disease. Future revenues are highly speculative and depend on success in one of the most complex areas of medicine. The chart reflects analysts' confidence in its scientific approach.
%20sales%20of%20the%20company%20Synaptogenix%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Synaptogenix-Inc.&v=1772513696148 "Schedule of future (projected) sales of the company Synaptogenix Inc.")
Future (projected) sales of companies in the market segment - Neuro
Synaptogenix is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases, particularly Alzheimer's disease. The company is working on a therapy aimed at restoring synaptic connections in the brain. This chart shows the forecast for the entire neuroscience market, where Alzheimer's disease remains one of the major unsolved problems.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513696179 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Synaptogenix is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its valuation is almost entirely dependent on research results. This curve, reflecting investors' risk appetite, affects the availability of capital to finance highly risky but potentially breakthrough developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513696217 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Synaptogenix Inc.
Synaptogenix is a biotech company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's. This is one of the most complex areas in pharmaceuticals. This chart shows its net losses—a massive investment in research in the hopes of creating a breakthrough drug, where the risk of failure is extremely high, but the potential reward is enormous.
Market segment marginality - Neuro
Synaptogenix is a clinical-stage biopharmaceutical company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors analyze it to assess the scientific potential of their approaches.
Market marginality as a whole
Synaptogenix is a biopharmaceutical company developing therapies for neurodegenerative diseases, particularly Alzheimer's disease. Their approach is based on restoring synaptic connections in the brain. This overall profitability curve is irrelevant to them. Their future depends solely on the success of their clinical programs in this highly complex field.
Employees in the company, segment and market as a whole
Number of employees in the company Synaptogenix Inc.
Synaptogenix is a clinical-stage biotech company focused on Alzheimer's disease. It operates with a very small team. This chart illustrates the typical biotech model, where the primary focus is on managing clinical trials rather than a large staff.
Share of the company's employees Synaptogenix Inc. within the market segment - Neuro
Synaptogenix is a biopharmaceutical company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart reflects its share of the total number of researchers in this complex field. It is an indicator of the scale of its clinical programs and the size of the scientific team working on new drugs.
Number of employees in the market segment - Neuro
Synaptogenix, Inc. is a late-stage clinical development biopharmaceutical company focused on treating Alzheimer's disease. This chart reflects employment trends in the high-risk field of neuroscience. Fluctuations in the hiring of scientists and clinicians are directly related to clinical trial results, which are often unpredictable in this field.
Number of employees in the market as a whole
Synaptogenix is a biotech company developing a treatment for Alzheimer's disease. Its future depends entirely on the results of clinical trials. The overall economic environment, reflected in this chart, influences investor sentiment and their willingness to fund extremely risky but potentially revolutionary projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Synaptogenix Inc. (SNPX)
Synaptogenix is a biotech company focused on treating Alzheimer's disease, one of the most complex and risky areas of R&D. The chart shows that the company's market value is a pure bet on the success of its clinical trials. The market value per employee (scientist) can be enormous, reflecting the potential market size in case of success, not current activity.
%20of%20the%20company%20Synaptogenix%20Inc.%20(SNPX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Synaptogenix-Inc.-SNPX&v=1772513696578 "Chart of market capitalization per employee (in thousands of dollars) of the company Synaptogenix Inc. (SNPX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its value is based on the potential of its clinical development pipeline. This chart demonstrates the market's high valuation of its scientific assets and its hopes for a breakthrough in this complex area of medicine.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513696580 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. The chart illustrates valuation in this highly complex area of medicine. It shows how the market values their scientific approach, where even small advances can lead to enormous value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513696598 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Synaptogenix Inc. (SNPX)
Synaptogenix is a clinical-stage biotech company specializing in developing treatments for Alzheimer's disease. This is high-risk, high-reward R&D. This chart shows the company's capital burn rate: the amount it spends on each scientist in this highly complex field.
%20Chart%20Synaptogenix%20Inc.%20(SNPX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Synaptogenix-Inc.-SNPX&v=1772513696600 "Company Profit Per Employee (in thousands of dollars) Chart Synaptogenix Inc. (SNPX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Synaptogenix is a clinical-stage biotech company focused on developing drugs for the treatment of Alzheimer's disease. This is one of the most complex and expensive areas of R&D. This metric (loss per employee) reflects the enormous cost of conducting multi-year clinical trials.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513696620 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Synaptogenix (SNPX) is a clinical-stage biotech company specializing in the treatment of Alzheimer's disease. It is an R&D company and is not profitable. This chart shows its capital burn rate: the operating loss per research team (following recent research setbacks).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513696622 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Synaptogenix Inc. (SNPX)
Synaptogenix is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart reflects the progress of monetizing its research. Revenue growth at this stage will depend on clinical trial results and potential partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Synaptogenix-Inc.-SNPX&v=1772513696633 "Sales chart per company employee Synaptogenix Inc. (SNPX)")
Sales per employee in the market segment - Neuro
Synaptogenix (SNPX) is a biotech company focused on treating neurodegenerative diseases, primarily Alzheimer's disease. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
Synaptogenix (SNPX) is a clinical-stage biotech company specializing in drugs for the treatment of neurodegenerative diseases such as Alzheimer's. The company has no commercial revenue yet. This chart illustrates a typical R&D situation: its entire scientific staff is working on developing future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Synaptogenix Inc. (SNPX)
Synaptogenix is a biotech company developing a drug to treat Alzheimer's disease. The bearish sentiment shown in this chart reflects extreme skepticism. Investors are betting on clinical trial failure, which is almost a statistical norm for the Alzheimer's drug "graveyard."
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Synaptogenix-Inc.-SNPX&v=1772513696655 "Short Shares Chart for the Company Synaptogenix Inc. (SNPX)")
Shares shorted by market segment - Neuro
Synaptogenix (SNPX) is a clinical-stage biotech focused on treating Alzheimer's disease. This chart shows the total short position volume across the entire neurosciences sector. This is an indicator of investor skepticism. If it's high, it means the market is skeptical of the success of clinical trials or regulatory approvals for the entire industry, which casts a shadow on SNPX.
Shares shorted by the overall market
Synaptogenix is a biotech focused on the R&D "graveyard" of Alzheimer's disease. This chart illustrates the overall market pessimism. When investors are afraid, they don't bet on miracles. They see the highest risk of failure and sell off shares of companies working in the most challenging R&D areas.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Synaptogenix Inc. (SNPX)
Synaptogenix (SNPX) is a biotech company working on Alzheimer's disease treatments. This is the holy grail of pharma, and the stock is extremely volatile. This oscillator shows when the hype around the trial data (above 70) or the disappointment with the results (below 30) reach an emotional peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Synaptogenix-Inc.-SNPX&v=1772513696671 "RSI 14 indicator chart for the company's stock Synaptogenix Inc. (SNPX)")
RSI 14 Market Segment - Neuro
Synaptogenix is a biopharma... (insufficient data, company appears to have ceased operations or been restructured). This chart reflects the overall sentiment in the neuroscience sector. It helps assess how oversold or overheated this entire speculative industry is.
RSI 14 for the overall market
Synaptogenix (SNPX) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the opportunity to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SNPX (Synaptogenix Inc.)
Synaptogenix is a biotech company developing drugs to treat neurodegenerative diseases, particularly Alzheimer's. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet on the success of clinical trials after past failures.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SNPX-Synaptogenix-Inc.&v=1772513696720 "A chart showing analyst consensus forecasts for the expected stock price. SNPX (Synaptogenix Inc.)")
The difference between the consensus estimate and the actual stock price SNPX (Synaptogenix Inc.)
Synaptogenix (SNPX) is a biotech company focused on developing drugs to treat neurodegenerative diseases, particularly Alzheimer's. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of this highly risky R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SNPX-Synaptogenix-Inc.&v=1772513696722 "A chart showing the difference between the consensus forecast and the actual stock price. SNPX (Synaptogenix Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Synaptogenix (SNPX) is a high-risk biotech betting on an R&D platform for Alzheimer's disease. This chart shows analysts' overall expectations for the entire neuroscience sector. It reflects whether experts believe a breakthrough in Alzheimer's treatment is possible or whether they view the sector as an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Synaptogenix (SNPX) is a micro-cap biotech company attacking Alzheimer's disease, one of the most complex and "failing" areas in R&D. This chart shows the overall risk appetite in the market, reflecting how willing investors are to back the riskiest, most "lottery" tickets in the world of science.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Synaptogenix Inc.
Synaptogenix is a biotech company focused on treating neurodegenerative diseases, primarily Alzheimer's disease. This is one of the most complex and risky areas in medicine. This chart represents an integrated assessment reflecting the company's extremely high sensitivity to clinical trial results and the availability of sufficient capital to conduct them.
AKIMA Market Segment Index - Neuro
Synaptogenix (SNPX) is a neurobiotech company seeking a cure for Alzheimer's. This is one of the most complex and risky areas in pharmaceuticals, where failures are common. This chart compares their composite index to the sector average, showing their position in this challenging race.
The AKIM Index for the overall market
Synaptogenix is a biotech company developing bryostatin-based drugs for the treatment of neurodegenerative diseases (Alzheimer's). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
